Immunovant, Inc. (IMVT)

Nasdaq · Healthcare · Biotechnology
$31.77-2.31%As of 2026-11-22 · USD
Last session low $31.61Last session high $32.77
52-week low $21.9352-week high $45.42
Market cap
$6.57B
Sector
Healthcare
Next earnings
2027-02-05 (est.)

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-19 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)51.3In the neutral range (30 to 70)
MACD (12, 26, 9)0.69Above its signal line (0.40); histogram 0.30
Bollinger %B (20, 2)53%Inside the bands (25.79 to 37.17)
SMA 2031.48Price is 0.9% above
SMA 5032.17Price is 1.2% below
SMA 20032.49Price is 2.2% below
ATR (20)4.75% of priceAverage true range per day
52-week position42%In the middle of the 21.93 to 45.42 range

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.

Insider filings, 90 daysNo purchases and 9 sales (about $896K).
Next earnings reportExpected on 2027-02-05 (the date is an estimate).

More in Biotechnology